An Open-label, Randomized, Single-dose, Two-treatment, Four-period, Fully Replicate Crossover Bioequivalence Study in Healthy Female Adult Participants Under Fasting Conditions Comparing the Test Product, Prontogest Solution for IM Injection With the Reference Product, Progesterone Injection

NCT07495007 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

26

Enrollment

INDUSTRY

Sponsor class

Conditions

Bioequivalance
Post-menopause

Interventions

DRUG: Progesterone IM of 100 mg
DRUG: Progesterone IM of 100 mg

Sponsor

Zi Diligence Biocenter

Collaborators

[object Object]